About BANZEL
For parents and caregivers of patients with seizures associated with Lennox-Gastaut
syndrome (LGS), a good day could be measured in unlikely ways. The simplest activities
are often out of reach. With fewer seizures, happiness might come from seemingly
small victories.
BANZEL (rufinamide) is a prescription medication approved for the adjunctive treatment of seizures
associated with LGS in children 4 years and older and adults.
BANZEL has been clinically proven to reduce seizures associated with LGS. In a clinical study of
patients with LGS, who were treated with BANZEL, in addition to their existing medications, BANZEL:
- reduced the frequency of tonic-atonic seizures (drop attacks)
- reduced the frequency of total seizures
- reduced the severity of seizures
Read
Important Safety Information and the Medication Guide about BANZEL and discuss it with your healthcare provider.
Patient safety and comfort is a primary concern. BANZEL has the power to reduce
seizures associated with LGS. Some anti-epilepsy drugs, including BANZEL, can cause
a rash which can be a sign of something more serious. Talk to your healthcare professional
immediately if a rash occurs. In clinical studies of epilepsy, the side effects patients commonly experienced were described as
mostly mild or moderate. Side effects typically went away in a short amount of time.
Additional benefits
In addition to delivering seizure control, BANZEL:
Always follow the recommendations of your healthcare provider and follow dosing instructions
exactly as prescribed.
From small victories
With control of seizures associated with LGS, BANZEL offers hope to families who
are looking for fewer seizures. With more seizure control, caregivers and their
loved ones can focus on the little things, the small victories. From these small
victories may come hope and happiness.
Ask your healthcare provider about adding BANZEL to an existing treatment.